Work

Photodynamic Therapy in Bladder Cancer Management: Integrated Innovations and Clinical Translation

Year: 2025

Type: article

Abstract: Despite Bacillus Calmette-Guérin therapy, non-muscle invasive bladder cancer (NMIBC) has 60-70% recurrence rates, necessitating bladder-preserving strategies. Photodynamic therapy (PDT) advances through: (1) Third-gen photosensitizers (e.g., Ce6-PVP) showing 89% 1-year recurrence-free survival in Phase III trials via pH-responsive tumor targeting (tissue ratio 23:1); (2) Nanocarriers (e.g., folate-targeted Au@TNA) achieving >95% pathologic complete responses in BCG-unresponsive cases; (3) PDT-PD-L1 combinations increasing CD8+ T-cell infiltration 4.3-fold, attaining 94% complete remission in carcinoma in situ. Safety profiles reveal <3% severe adverse events (vs. 6.8% chemotherapy) with 84% cystectomy avoidance. Emerging innovations include glutathione-responsive activatable PSs (NCT05246774) and AI-driven light dosing. These developments establish PDT as a pivotal organ-sparing therapy for NMIBC.

Source: Photodiagnosis and Photodynamic Therapy

DOI: 10.1016/j.pdpdt.2025.105168

Authors: Jiahao Cui, Qing-jun Meng

Institution: First Affiliated Hospital of Zhengzhou University

Language: English

Topic: Photodynamic Therapy Research Studies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,610